RxDoctor Payments Data

Jason Khadavi

Foot & Ankle Surgery · Encino, CANPI 1831534197

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for foot & ankle surgery clinicians in CA, where the typical reported total is $2,067.

$1,220in general payments, 2019–2025

Across 55 payments — averaging $22.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Paratek Pharmaceuticals, Inc.$156
  • Amgen$121
  • Integra Lifesciences Corporation$108
  • Smith+Nephew$103
  • Vertex$66
  • Organogenesis Inc.$65
  • plus $602 from 23 others
$25,773in research payments, 2019–2025

Across 3 payments — averaging $8591.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$26K

What the payments were for

  • Food & beverage$1,220100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,220 in reported general payments places this provider in the 35th percentile of 1,126 foot & ankle surgery providers in California.

See all foot & ankle surgery providers in California →

Medicare billing

Part B allowed, 2024
$418,249
Medicare patients
562
Services billed
2,675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole11$7,988
Ciclopirox98$2,004
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip36$603
Cephalexin20$533
Terbinafine Hcl33$166
Gabapentin31$133
Ammonium Lactate14$132
Mupirocin21$87
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen21$83
Ibuprofen33$77
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav19$65
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$27
Prednisone15$26

Paid to pharmacies, not to this prescriber.

Other foot & ankle surgery in Encino

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →